Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS
Publication
, Conference
Morgans, AK; Sweeney, C; Wallis, CJD; Halabi, S; Armstrong, AJ; Adorjan, P; Ghadessi, M; Verholen, F; Grimm, M-O
Published in: JOURNAL OF CLINICAL ONCOLOGY
2024
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Morgans, A. K., Sweeney, C., Wallis, C. J. D., Halabi, S., Armstrong, A. J., Adorjan, P., … Grimm, M.-O. (2024). Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).
Morgans, Alicia K., Christopher Sweeney, Christopher J. D. Wallis, Susan Halabi, Andrew J. Armstrong, Patrick Adorjan, Mercedeh Ghadessi, Frank Verholen, and Marc-Oliver Grimm. “Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.
Morgans AK, Sweeney C, Wallis CJD, Halabi S, Armstrong AJ, Adorjan P, et al. Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.
Morgans, Alicia K., et al. “Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.
Morgans AK, Sweeney C, Wallis CJD, Halabi S, Armstrong AJ, Adorjan P, Ghadessi M, Verholen F, Grimm M-O. Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS. JOURNAL OF CLINICAL ONCOLOGY. 2024.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences